Julian Canovas joined CRG in 2024 and serves as a Senior Accountant. Mr. Canovas primarily focuses on fund accounting, compliance, and reporting for the Fund's leverage facilities. Prior to joining CRG, Mr. Canovas worked in fund administration at Alter Domus as a fund accountant for various real estate and credit opportunity funds. 

Mr. Canovas received a bachelor's from Ensign College where he earned a degree in Accounting and an M.B.A. from Western Governors University. 

Adam W. Park joined CRG in 2024 and serves as the firm’s General Counsel.

Prior to joining CRG, he served as Chief Compliance Officer of MSC Income Fund, Inc. and as Assistant General Counsel, Assistant Compliance Officer and Assistant Secretary of Main Street Capital Corporation, an NYSE listed business development company. Prior to joining Main Street, Mr. Park practiced corporate and securities law at Baker & Hostetler LLP, where he counseled companies in capital markets transactions, mergers and acquisitions and advised on a wide range of corporate governance matters, and at Eversheds Sutherland (US) LLP, where his practice focused on the formation, regulation and operation of public and private funds, including business development companies.

Mr. Park received a B.A. in philosophy from the College of William and Mary and J.D. (magna cum laude) from the George Mason University School of Law.

Mr. Park is admitted to the State Bar of Texas.

Anna Duffy joined CRG in 2024 and serves as an Associate on the Investment Team. Ms. Duffy’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments. Prior to CRG, Ms. Duffy was an associate with Wells Fargo’s Healthcare Investment Banking Group.

Ms. Duffy graduated from the University of North Carolina at Chapel Hill with a Bachelor of Science in Business Administration.

Ronan McIntosh joined CRG in 2024 and serves as a Vice President on the Investment Team. Mr. McIntosh’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments. Prior to CRG, Mr. McIntosh was a Vice President at Revelstoke Capital Partners where he evaluated and executed investments across the healthcare industry and served on the board of directors of Rarebreed Veterinary Partners and The Care Team. Mr. McIntosh was previously an Analyst with J.P. Morgan’s Healthcare Investment Banking Group.

Mr. McIntosh graduated summa cum laude from the University of Denver, where he earned a Bachelor of Science in Finance and International Business.

Christian Solcher joined CRG in 2024 and serves as Vice President, Financial Planning & Analysis. Prior to joining CRG, he worked as a Vice President at Crescent Capital where he supported various risk management and operational functions. Previously, Mr. Solcher also was the Director of Finance at Pickering Energy Partners where he led all accounting and finance functions.

Mr. Solcher graduated from Vanderbilt University with a dual major in Engineering and Economics as well as a Master of Accountancy from their Business School (Owen).

Max Steiner joined CRG in 2024 and is an Associate on the Investor Relations team, supporting the firm's capital raising and investor reporting activities. Prior to joining CRG, Mr. Steiner worked as a Business Development Analyst at BroadRiver Asset Management and, prior to BroadRiver, he began his career at Morgan Stanley on the Finance team for the Exotic Corporate Derivatives trading desk. 

Max graduated from Colby College with a Bachelor of Arts in Government and Economics

Emily Willenbring joined CRG in 2023 and serves as an Associate on the Investment Team. Ms. Willenbring’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments. Prior to CRG, Ms. Willenbring was an analyst with Citigroup’s Healthcare Investment Banking Group.

Ms. Willenbring graduated from the University of Georgia with a Bachelor of Business Administration in Finance and Accounting.

Sebastian Arango is a Managing Director and Head of Capital Formation, leading the Firm’s global fundraising and investor relations function. He joined CRG in 2023 and has over 20 years of investment and advisory experience. 

Prior to CRG, Mr. Arango was a Managing Director and senior marketing and capital markets professional at King Street Capital Management. At King Street, he worked closely with institutional allocators and consultants across the United States, Canada, and Latin America, growing strategic partnerships and leading capital raising initiatives across public and private credit vehicles. Prior to King Street, Mr. Arango was a restructuring banker in Blackstone’s Restructuring & Reorganization Group. Mr. Arango began his career as an investment banking and fixed income analyst at Citigroup. 

Mr. Arango received a Bachelor of Arts from Vanderbilt University in 2000, where he graduated magna cum laude as a Chancellor’s and Dean’s Select Scholar. He received an M.B.A. from the Kellogg School of Management and a J.D. from the Northwestern Pritzker School of Law in 2006. 

Young Jun (Alex) Kim joined CRG in 2023 and serves as an Associate on the Investor Relations & Operations teams, supporting the firm's investor reporting activities as well as operational functions encompassing valuation, leverage, and compliance. Prior to CRG, Mr. Kim worked as an Equity Research Associate within the Aerospace & Defense and Airlines team at Jefferies.

Mr. Kim graduated from Carnegie Mellon University with a Bachelor of Science in Economics.

Peter Grant joined CRG in 2022 and leads its quantitative analytics function. Mr. Grant is responsible for CRG’s data environment as well as portfolio and fund analytics. Prior to joining CRG, Mr. Grant has led similar functions in the insurance, nuclear, banking, and private equity spaces.

Mr. Grant graduated magna cum laude in finance from Temple University’s Fox School of Business in Philadelphia, PA.

Kirby Lyles joined CRG in 2022 and is the Executive Assistant to Luke Düster, CIO, and David Carter, Partner. Ms. Lyles also serves as Office Manager to the Boulder Office.

Prior to joining CRG, Ms. Lyles held various executive support positions with firms and organizations including Eaton Partners, Gibson Dunn and Crutcher and Texas Medical Center.

Ms. Lyles graduated from Sam Houston State University in Huntsville, Texas.

Sean Scanlan joined CRG in 2021 and serves as a Vice President of the Investment Team. Mr. Scanlan's primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments. Prior to CRG, Mr. Scanlan was an Associate at Revelstoke Capital Partners where he evaluated and executed investments across the healthcare industry. Mr. Scanlan was previously a member of the Healthcare Investment Banking Group at Raymond James.

Mr. Scanlan graduated with distinction from the University of Colorado at Boulder, where he earned a Bachelor of Science in Business Administration with an emphasis in Finance.

JP Giroux joined CRG in 2021 and serves as a Senior Associate on the Investment Team. Mr. Giroux’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments. Prior to CRG, Mr. Giroux was an Associate with Jefferies’ Healthcare Investment Banking Group.

Mr. Giroux graduated from Stevens Institute of Technology with a Bachelor of Science in Quantitative Finance.

Meredith Gamble joined CRG in 2021 and is a member of the Investor Relations team, supporting the firm's capital raising and investor reporting activities. Ms. Gamble also serves as Head of ESG and a member of CRG’s ESG Committee. Prior to CRG, Ms. Gamble worked in Investor Relations, Financial Planning and Corporate Development at Occidental Petroleum and Western Midstream.

Ms. Gamble graduated Cum Laude with a Bachelor of Arts from Rice University in Houston, TX.

Kyle Simmons joined CRG in 2019 and serves as Senior Accountant. Mr. Simmons is primarily responsible for the management company accounting as well as supporting the accounting managers with Fund III duties such as financial reporting, valuations, leverage (inclusive of the asset-backed securitization), and compliance.  Prior to joining CRG, he worked as an assurance professional within the Private Client Services group at PricewaterhouseCoopers. 

Mr. Simmons graduated from Texas Lutheran University with a Bachelor of Business Administration in Accounting and a Master of Accountancy.

Brian Englander joined CRG in 2019 and serves as a Vice President on the Investment Team. Mr. Englander’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments.   Prior to CRG, Mr. Englander was an analyst with Citigroup’s Technology Investment Banking Group.

Mr. Englander graduated from the University of Colorado at Boulder with a Bachelor of Science in Business Administration with an emphasis in Finance.

Ben Wessner joined CRG in 2017 and serves as a Principal on the Investment Team. Mr. Wessner’s primary focuses are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio investments.   Prior to CRG, Mr. Wessner was an analyst with Piper Jaffray’s Healthcare Investment Banking Group.

Mr. Wessner graduated from the Charles H. Dyson School at Cornell University with a Bachelor of Science in Applied Economics and Management.

Carolyn Cranor joined CRG at its formation in 2003 as Executive Assistant to Charles W. Tate, the Chairman and Founder of the Firm.  Prior to that, she was Mr. Tate’s Executive Assistant at Hicks, Muse, Tate and Furst Incorporated from 1996 to 2003.   In the past, Ms. Cranor has also held various H.R. management, office management and executive assistant positions with Gardner-Denver/Cooper Industries at its Dallas/Sunnyvale, Texas offices.

Harlan F. Weisman, M.D. is the founder and Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing successful strategies for driving innovation in healthcare products and services. He is co-founder, Board Director and Chief Scientific Officer for Mycrobiomics, Inc.  He is also on the board of directors of ControlRad Systems, Inc and Hutchison Biofilm Medical Solutions Ltd, and is an advisor to the Israel Biotechnology Fund, the Johns Hopkins Institute for Basic Biomedical Sciences, Memorial Sloan Kettering Cancer Center and BioMotiv, a medical product accelerator company.

Previously, Dr. Weisman was Chairman and CEO of Coronado Biosciences, Inc., a company focused on developing treatments for immune mediated inflammatory disorders.  Prior to Coronado, he served over 20 years as a senior executive at Johnson & Johnson including as Chief Science and Technology Officer of the J&J Medical Devices Group, Company Group Chairman, J&J Pharmaceutical Research & Development, President of Centocor R&D and also served on the board of directors of J&J Development Corporation (JJDC). Before joining industry, Dr. Weisman was Assistant Professor of Medicine and Director of the Experimental Cardiac Pathology Laboratory at the Johns Hopkins University School of Medicine, and Consultant Cardiologist at Johns Hopkins Hospital.

Dr. Weisman has authored more than 100 articles and book chapters about cardiovascular disease, medical product development, healthcare policy and organizational development. He is a frequent invited speaker at international meetings on medical innovation, health policy and product development strategy.

Board Positions

- Vice Chairman, President & CEO of TFF Pharmaceuticals
- Center for Discovery and Innovation

Mark McClellan is the Director of the Robert J Margolis Center for Health Policy and the Margolis Professor of Business, Medicine and Health Policy at Duke University. Prior to this, Mark was a Senior Fellow and Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. His work focuses on strategies and policy reforms to improve health care, including such areas as accountable care, better evidence from real-world practice, and more effective drug and device innovation. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, Medicare and Medicaid payment reforms, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care.

Dr. McClellan is the founding chair and a current board member of the Reagan-Udall Foundation for the FDA, is co-chair of the Quality Alliance Steering Committee, chairs the National Quality Forum’s partnership on clinician quality measurement, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He has also served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and as Deputy Assistant Secretary for Economic Policy at the Department of the Treasury.  He was previously an associate professor of economics and medicine with tenure at Stanford University, and has twice received the Kenneth Arrow Award for Outstanding Research in Health Economics.

Board Positions

- Cigna
- Johnson & Johnson
- Alignment Health Care
- PognomIQ

Scott Li joined CRG in 2015 and serves as a Partner and member of CRG’s investment committee.  Mr. Li has been focused on the healthcare industry as an advisor, investor and executive for over 15 years.  Mr. Li helps lead investment sourcing, diligence, and execution for CRG activity in various sectors, including healthcare services.

Prior to joining CRG, Mr. Li was an investment banker with Hammond Hanlon Camp LLC (“H2C”). Mr. Li’s previous investment banking experience also includes positions in the Life Sciences Investment Banking Group of Lazard and the North American M&A Group of J.P. Morgan. Prior to joining H2C, Mr. Li was the Chief Financial Officer of pingmd, a provider of an online communication platform for primary care physicians. Mr. Li was also previously an Associate with ABS Ventures, the venture capital arm of DB Capital Partners. Mr. Li received an AB in economics from Princeton University in 1997 and an M.B.A from the Wharton School at the University of Pennsylvania in 2004.

Colin Eckersley joined CRG in 2014 and serves as Controller. Mr. Eckersley is responsible for all fund management functions as well as supervising the third-party fund administrator and facilitating annual audits. Additionally, he manages the human resource, compliance, insurance, and information technology functions.

Mr. Eckersley is a licensed CPA and graduated from the C.T. Bauer College of Business at the University of Houston with a Bachelor of Business Administration, specializing in accounting and a Masters in Accounting.

Andrei Dorenbaum is a partner and member of CRG’s Founders Group. Mr. Dorenbaum joined CRG in 2010 and became an independent advisor in 2023. He is responsible for managing the legal function of the firm’s investment and financing activities, which includes structuring investments, identifying underwriting risks during diligence and negotiating terms. In addition, he supports the structuring and negotiation of the funds’ financing facilities with banks and other financing counter parties. He is also responsible for managing bankruptcies and contested workouts. Mr. Dorenbaum manages operations in the Houston office and oversees the operation of CRG’s back-office and accounting group. Prior to joining CRG, Mr. Dorenbaum was an assistant general counsel at Highland Capital where he completed over $2 billion in negotiated investments and structured derivative financing arrangements.

Mr. Dorenbaum received a B.A. (magna cum laude) in applied economics and J.D. (cum laude) both from the University of Michigan. He also earned an LL.M. from Georgetown University School of Law.

Mr. Dorenbaum is admitted to the State Bar of California.

Phil Houston is a nationally recognized authority on deception detection, critical interviewing, and elicitation. His 25 year career with the Central Intelligence Agency was highlighted by his service as a senior member of the Office of Security. In that capacity he conducted thousands of interviews and interrogations for the CIA and other federal agencies, both as an investigator and as a polygraph examiner. He is credited with developing a detection of deception methodology currently employed throughout the U.S. intelligence and federal law enforcement communities. Mr. Houston introduced the detection of deception methodology to the corporate world with the co-founding of Business Intelligence Advisors, where he served as Executive Vice President.

Mr. Houston holds a B.A. in Political Science from East Carolina University in Greenville, N.C.

David Carter is a member of CRG’s Founders Group and serves as Partner and member of CRG’s Investment Committee. Mr. Carter joined CRG in 2003 and has more than 30 years of investment and advisory experience. Mr. Carter leads the due diligence efforts related to CRG’s investments in the medical device, specialty pharma, drug delivery, biopharma and tools & diagnostic sectors. Mr. Carter, in addition to focusing on sourcing, execution and monitoring existing CRG investments is responsible for staffing CRG deal teams.  Prior to joining CRG, Mr. Carter was a partner at Palestra Capital, a hedge fund focused on risk arbitrage and special situations. Before joining Palestra, Mr. Carter was a high yield analyst at Furman Selz LLC, where he was responsible for coverage of healthcare-related high yield debt. Previously, Mr. Carter was an investment banking analyst in the Healthcare Group at Chemical Bank and a research assistant in the Mergers & Acquisitions Group of Morgan Stanley.  Over the course of his career, Mr. Carter has closed in excess of $5 billion of financing activity.

Mr. Carter received a Bachelor of Science in finance from The Pennsylvania State University in 1988. He received a Master of Arts degree in information science and systems in 1994 and an M.B.A. in 1996, both from Columbia University.

Luke Düster is a member of CRG’s Founders Group, serves as Chief Investment Officer, ESG Champion and a Member of CRG’s Investment Committee and ESG Committee. He is also responsible for portfolio management and portfolio company exits.  Mr. Düster also serves on the board of directors of several CRG portfolio companies, both as a director and as an observer, and serves portfolio company senior management teams as an advisor on financial, strategic and operational initiatives.  He has led investments in companies such as Neotract, Nevro, Omeros, BioDelivery Sciences, Strongbridge Biopharma, Silk Road Medical, NanoString Technologies and many others.

Prior to CRG, Mr. Düster was an investment banker at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of M&A assignments.  Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare advisory firm.

Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. He received an M.B.A with honors from the Wharton School at the University of Pennsylvania in 2004. 

Nathan Hukill is a member of CRG’s Founders Group and is a member of CRG’s ESG Committee. Mr. Hukill oversees all aspects of the investment process, including investment sourcing, due diligence, portfolio construction and portfolio management. Mr. Hukill also oversees the investor relations process, including fund raising, reporting and limited partner relationship management. CRG’s accounting, finance, compliance and legal teams also report to Mr. Hukill.

Mr. Hukill joined CRG in 2009 to implement investment strategies he had uncovered while beginning his investment career at Salomon Smith Barney, where he managed a portfolio of approximately $800 million, and Highland Capital Management, where he invested and managed approximately $4.5 billion of healthcare credit assets.

Mr. Hukill graduated Phi Beta Kappa, summa cum laude from the University of Colorado at Boulder in 1999 with a Bachelor of Science in business administration. He received an M.B.A. from the Darden Graduate School of Business at the University of Virginia in 2005. Mr. Hukill is a former professional cyclist who had the unique challenge of first competing against Lance Armstrong when they were both 16 years old.